Morgan Stanley analyst Sean Laaman raised the firm’s price target on Argenx (ARGX) to $1,160 from $1,110 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target lowered to $1,091 from $1,124 at Citi
- Argenx price target raised to EUR 880 from EUR 850 at Barclays
- Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
- argenx: Leadership Continuity and Pipeline Milestones Underpin Sustained Buy Rating and $1,006 Price Target
- argenx: Leadership Transition, Pipeline Strength, and Commercial Expansion Support Buy Rating and $915 Target